Get Support

Search global stocks & ETFs...Ctrl K

Learn Mode

JNJ - Johnson & Johnson

685

$227.83

$3.56 (1.590%)

5/13/26, 3:33 PM

3.26/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

JNJ

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$549.95B

Industry

Pharmaceuticals

EPS (TTM)

$8.60

P/E (TTM)

26.14

Div & Yield

$5.36 (2.35%)

FCF Payout Ratio

72.75%

P/S (TTM)

5.71

P/B

6.77

Diluted Shares

2.45B

Ex-Dividend

2026-05-26

Next Earnings

07-14

Forward P/E

19.16

Payout Ratio

61.50%

P/FCF (TTM)

30.92

FCF Yield

3.23%

Earnings Yield

3.83%

52 Week Range

Score Card

Explore Scores Tab

3.26

Average

Johnson & Johnson has grown revenue at 7.87% over the past year, which suggests sales are increasing. Also, it has a free cash flow margin of 18.46%, which suggests the company is very profitable.

Valuation Model

Key Score

5.00

Very Good

Management

4.00

Good

Growth

3.00

Average

Profitability

5.00

Very Good

Fin. Health

2.00

Bad

Dividends

4.00

Good

Analyst

1.00

Very Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

Filter Form Types

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-04 16:58:59

Form SCHEDULE 13G

Unknown Form Type

Filed on 2026-05-01 08:39:37

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-27 18:23:40

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-27 18:21:49

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-27 18:17:20

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-27 18:13:34

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-27 18:12:17

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-27 18:06:44

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-27 18:05:50

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-27 18:01:05

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-27 17:48:43

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-27 17:43:28

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$299.25

31.4%

Avg:

$258.36

13.4%

Low:

$171.70

-24.6%

(% change is relative to the current stock price: $227.83)

Analyst Recommendations

Go to Analyst Tab

3.81

Good

19%

Strong Buy (6)

44%

Buy (14)

38%

Hold (12)

0%

Sell (0)

0%

Strong Sell (0)

About

Website
https://www.jnj.com/
Address
One Johnson & Johnson Plaza, New Brunswick NEW JERSEY, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=200406

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,200 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).

IPO Date

1944-09-25

Industry

Pharmaceuticals

Total Employees

138,200

Exchange

New York Stock Exchange, Inc.

Reporting Currency

USD

GICS

Pharmaceuticals

GICS Sub

Pharmaceuticals

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences